0001193125-13-170515.txt : 20130424 0001193125-13-170515.hdr.sgml : 20130424 20130424164127 ACCESSION NUMBER: 0001193125-13-170515 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20130424 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130424 DATE AS OF CHANGE: 20130424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CYNOSURE INC CENTRAL INDEX KEY: 0000885306 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 043125110 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51623 FILM NUMBER: 13779673 BUSINESS ADDRESS: STREET 1: 5 CARLISLE ROAD CITY: WESTFORD STATE: MA ZIP: 01886 BUSINESS PHONE: (978) 256-4200 MAIL ADDRESS: STREET 1: 5 CARLISLE ROAD CITY: WESTFORD STATE: MA ZIP: 01886 8-K 1 d526631d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 24, 2013

Cynosure, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   000-51623   04-3125110

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

5 Carlisle Road, Westford, MA   01886
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (978) 256-4200

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On April 24, 2013, Cynosure, Inc. (“Cynosure”) and Palomar Medical Technologies, Inc. (“Palomar”) issued a joint press release announcing the anticipated date of Cynosure’s annual meeting of stockholders and Palomar’s special meeting of stockholders and the anticipated closing of the acquisition of Palomar by Cynosure pursuant to the agreement and plan of merger, dated as of March 17, 2013, among Palomar, Cynosure and Commander Acquisition Corp. The joint press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

 

  (d) Exhibits

See the Exhibit Index attached to this Current Report on Form 8-K, which is incorporated herein by reference.

SAFE HARBOR STATEMENT

This Current Report on Form 8-K contains a forward-looking statement relating to the expected closing of the merger transaction between Cynosure and Palomar. This forward-looking statement is neither a promise nor a guarantee, but involves risks and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statement. These risk factors include, but are not limited to, failure to receive approval from the stockholders of Cynosure or Palomar or to satisfy other conditions to the parties’ obligations to complete the merger, the risk that competing offers for Palomar will be made and/or other factors, which are detailed from time to time in reports that Cynosure or Palomar file with the Securities and Exchange Commission (the “SEC”), including their reports on Form 10-K for the year ended December 31, 2012, any subsequently filed quarterly reports on Form 10-Q and the Cynosure Registration Statement on Form S-4 (File No. 333-187895). Readers are cautioned not to place undue reliance on this forward-looking statement, which speaks only as of the date hereof. Neither Cynosure nor Palomar undertakes any obligation to release publicly the result of any revisions to the forward-looking statement that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

ADDITIONAL INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT

In connection with the proposed transaction between Cynosure and Palomar, Cynosure filed a Registration Statement on Form S-4 (File No. 333-187895) with the SEC on April 12, 2013. The Registration Statement includes a joint proxy statement of Cynosure and Palomar that also constitutes a prospectus of Cynosure. Palomar and Cynosure also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC (IF AND WHEN THEY BECOME AVAILABLE) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint proxy statement/prospectus and other relevant documents filed by Cynosure and Palomar with the SEC (if and when they become available) at the SEC’s website at www.sec.gov. You may also obtain these documents by contacting Cynosure’s Investor Relations Department at (617) 542-5300 or CYNO@investorrelations.com, or by contacting Palomar’s Investor Relations Department at (781) 993-2411 or ir@palomarmedical.com.

Cynosure and Palomar and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Cynosure’s directors and executive officers is available in the joint proxy statement/prospectus under the heading “Information About Cynosure’s Directors, Officers and 5% Stockholders.” As of April 5, 2013, Cynosure’s directors and executive officers beneficially owned approximately 2.9 million shares, or 17.1%, of Cynosure’s Class A common stock. Information about Palomar’s directors and executive officers is available in Palomar’s proxy statement dated April 4, 2012 for its 2012 Annual Meeting of Stockholders and in the joint proxy statement/prospectus. As of March 15, 2013, Palomar’s directors and executive officers beneficially owned approximately 2.7 million shares, or 13.1%, of Palomar’s common stock. Additional information regarding the interests of Palomar’s directors and executive officers in the proposed transaction, including information relating to the acceleration of Palomar equity awards; the election of Joseph P. Caruso, Palomar’s

 

2

President, Chief Executive Officer and Chairman of the Board of Directors, as Cynosure’s President and Vice Chairman of the Board of Directors; amendments to existing Palomar employment agreements; a new employment agreement between Cynosure and Mr. Caruso; indemnification and insurance matters relating to Palomar directors and executive officers; and golden parachute compensation, can be found in the joint proxy statement/prospectus under the heading “Interests of Directors and Executive Officers of Palomar in the Merger.” Investors should read the joint proxy statement/prospectus carefully before making any voting or investment decisions. You may obtain free copies of any documents described above from Cynosure or Palomar using the sources indicated above.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CYNOSURE, INC.
Date: April 24, 2013     By:   /s/ Timothy W. Baker
       

Timothy W. Baker

Executive Vice President and Chief Financial Officer

 

4

EXHIBIT INDEX

 

Exhibit
No.

   

Description

99.1    Joint Press Release issued on April 24, 2013
 EX-99.1 2 d526631dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

Contacts:   

 

Scott Solomon

   

 

Kerry McAnistan

Vice President    Investor Relations Assistant
Sharon Merrill Associates, Inc.    Palomar Medical Technologies, Inc.
617.542.5300    781-993-2411
cyno@investorrelations.com    ir@palomarmedical.com

Cynosure and Palomar Announce Date for Stockholder Meetings

Westford, MA and Burlington, MA– April 24, 2013 – Cynosure, Inc. (NASDAQ: CYNO) and Palomar Medical Technologies, Inc. (NASDAQ: PMTI) today announced that the 2013 Annual Meeting of Cynosure Stockholders and the Special Meeting of Palomar Stockholders are scheduled to be held on June 24, 2013. Cynosure and Palomar stockholders of record at the close of business on May 21, 2013 will be entitled to notice of and to vote at the respective stockholder meetings.

At the meetings the Cynosure and Palomar stockholders will be asked to approve the acquisition of Palomar by Cynosure in a transaction valued at approximately $294 million. The execution of the definitive agreement related to the transaction was previously announced on March 18, 2013. Assuming Cynosure and Palomar stockholders approve the transaction, the merger is expected to close by the end of June 2013.

About Cynosure

Cynosure develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, visit Cynosure’s website at www.cynosure.com.

About Palomar

Palomar designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women’s and men’s skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry’s technology leader, Palomar has invested in creating cosmetic laser and IPL systems that

put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter (“OTC”) clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). This OTC clearance allows the PaloVia® Skin Renewing Laser® to be marketed and sold directly to consumers without a prescription. For more information on Palomar and its products, visit Palomar’s website at www.palomarmedical.com for professional products or palovia.com for consumer products.

Safe Harbor Statement

This press release contains a forward-looking statement relating to the expected closing of the merger transaction between Cynosure and Palomar. This forward-looking statement is neither a promise nor a guarantee, but involves risks and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statement. These risk factors include, but are not limited to, failure to receive approval from the stockholders of Palomar or Cynosure or to satisfy other conditions to the parties’ obligations to complete the merger, the risk that competing offers for Palomar will be made and/or other factors, which are detailed from time to time in Cynosure’s and Palomar’s SEC reports, including their reports on Form 10-K for the year ended December 31, 2012, any subsequently filed quarterly reports on Form 10-Q and the Cynosure Registration Statement on Form S-4 (File No. 333-187895). Readers are cautioned not to place undue reliance on this forward-looking statement, which speaks only as of the date hereof. Neither Cynosure nor Palomar undertakes any obligation to release publicly the result of any revisions to the forward-looking statement that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Additional Information about the Proposed Transaction and Where to Find It

In connection with the proposed transaction, Cynosure filed a Registration Statement on Form S-4 (File No. 333-187895) with the Securities and Exchange Commission (“SEC”) on April 12, 2013. The Registration Statement includes a joint proxy statement of Cynosure and Palomar that also constitutes a prospectus of Cynosure. Palomar and Cynosure also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC (IF AND WHEN THEY BECOME AVAILABLE) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. You may obtain a free copy of the joint proxy statement/prospectus and other relevant documents filed by Cynosure and Palomar with the SEC (if and when they become available) at the SEC’s website at www.sec.gov. You may also obtain

these documents by contacting Cynosure’s Investor Relations Department at (617) 542-5300 or CYNO@investorrelations.com, or by contacting Palomar’s Investor Relations Department at (781) 993-2411 or ir@palomarmedical.com.

Cynosure and Palomar and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Cynosure’s directors and executive officers is available in the joint proxy statement/prospectus under the heading “Information About Cynosure’s Directors, Officers and 5% Stockholders.” As of April 5, 2013, Cynosure’s directors and executive officers beneficially owned approximately 2.9 million shares, or 17.1%, of Cynosure’s Class A common stock. Information about Palomar’s directors and executive officers is available in Palomar’s proxy statement dated April 4, 2012 for its 2012 Annual Meeting of Stockholders and in the joint proxy statement/prospectus. As of March 15, 2013, Palomar’s directors and executive officers beneficially owned approximately 2.7 million shares, or 13.1%, of Palomar’s common stock. Additional information regarding the interests of Palomar’s directors and executive officers in the proposed transaction, including information relating to the acceleration of Palomar equity awards; the election of Joseph P. Caruso, Palomar’s President, Chief Executive Officer and Chairman of the Board of Directors, as Cynosure’s President and Vice Chairman of the Board of Directors; amendments to existing Palomar employment agreements; a new employment agreement between Cynosure and Mr. Caruso; indemnification and insurance matters relating to Palomar directors and executive officers; and golden parachute compensation, can be found in the joint proxy statement/prospectus under the heading “Interests of Directors and Executive Officers of Palomar in the Merger.” Investors should read the joint proxy statement/prospectus carefully before making any voting or investment decisions. You may obtain free copies of any documents described above from Cynosure or Palomar using the sources indicated above.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

GRAPHIC 3 g526730ex99_1pg1.jpg GRAPHIC begin 644 g526730ex99_1pg1.jpg M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$" M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`P,#_\``$0@`1`+&`P$1``(1`0,1`?_$`/(``0`!`P4!`0`````` M```````)!@<(`0,$!0H""P$!```'`0$```````````````$"`P0%"`D'!A`` M``4#`@,$!`4)$0L*!P$``0(#!`4`!@<1""$2$S$4%0E!82(647&1T1>A,F*B M(R2V.`KP@;'!0I(EE7;6-W>WUU@Y&N%RTN)$5#5&&'B8@C-#'IQDI$0`!`P(#!`0$#@T*!`<````!``(#$002!08A,1,'07$R"%&!(A1A MD<%""HD-3S?5VWCD M7$VV'&LS(1$]=LJPG+IDHAXX9N6+)PJNWBTEW#-1)=-JQ8MWDDX)S`!BHHZ\ M!X\_N]QK/5&JM>:9[O/+^\GM,YS.YCN+R6![F/CC<7-B#G1EK@R.-L]U(VM' M-CBKL*V6Y*9!D^4:;S?FAJB".;+[.)T4#)&M0QH:T%Q)PM:*!K1N:!N`"[RLPK)*(E$2B)1$HB41*(E$2B) M1$HB41"V>)TN)M<3>&'E^)M#B%*BAKN61?E&;16WGLEK%=W%A?VL3)[J":."058Y['-:[97R20`[80=E=FU&4Y!R3I MVPC9N)D7\>)BOF3&39.W;$Q5#(G*\;-UE5FPE6*)!ZA0T,&G;2TSK)\PNI;* MPN[:>\@)$D<PO[6%EQ/I^3YJR:M%U$1.14\D^6B'Z+XL9+RD#(=(WM,Y> M&='9R3!PF)0,DNV7)V"'M$,4P:E,`CC7L MF6V=W;2YC#7B1,E8Z2.A`.-C7%S:$@'$!0D`[2HRY??P6[+R>"9EI)3"]S'! MCJBHPN(#34`D4)J-J[70?7IZ./I^3YZR:M%PG\C'134SV5D648S(8"*.Y%XW M9-2F-]:0SAT=%$IC`'`-0$:M+[,+#++93PV]J#0OE>V-@)W`N>0/LJO;V MUS=RB"TC?+.=S6-+G'J#02MQF\:2#=)XP>-7[)UN[6^MVW5E+'-:O%6O8X/8X>@YI(/B*DFAFMY3#<,=',W>UP+7# MK!H0N44-1`-1XCH'$1X#ZN%7"IGW?[A,V/=73*U%W=LVRJH/,5N M#YXM;T<9$>PIDK;MM0.'^=&'TUSC[M[/G0[TFN.;EW66TRU[[.T>D(M.0;>21AG$W$H3#DI3M8E>49)2C@IP4$ MAD(]18KM8IP2-H)2&`0*.G8-)>D+M-!]'Y_'YP']*LFK16MN MK->+K&O.%L"\KQC;8N:XHTDK"H39EF$?(-3O%V!2)S2R18I!T+IN8H)*K)G- MPY0'6O.-2Y-/G^36M=/CT^,>W]'ZM11 M=')W-;<(LFVF[C@H=PJGUDF\I,QTYI(J"*C9445]:Y7F=\PR6-M/-� MF.-[P#OH2T$`TVT6W'77:TPY*RB+GMZ5>F(=0&<;.QC]T9)/05%"MVCE542) M@(UM3N%7-`J>M=PW=-793J-'3=VFFH=$QVKA)P0BR?!1(YT3'*5 M4@CQ*(ZA\%9:"XM[EI?;2,D8'%I+7!P!&\$@FA'2-X5B^.2(X96N:XBM""-A MW';T+?T'T?G\?G`?TJK*1:Z#Z]/3Q]/R?-1$T'UZ^CCZ/D^>B)I\>GQCV_H_ M5HBYB'_-AK\(_F[`HBW:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*( ME$2B)1$HB41*(E$2B)1$HB41*(E$4;?F5>97CCRS<3_`"?S?G%F MUWE&3W=M:36EL)G.F#R'`O:R@P-<:U=7;LHOCM9ZSLM%V45[?122QRR%@#*5 M!`KMJH=/[6!M8_HM[B/VUQC^^FM@/H.ZV_/64_>W'XM>XC]M<8_OII]!W6WYZRG[VX_%I\_NGO\)=>FQ/[6!M8_HM[B/VUQC^^ MFGT'=;?GK*?O;C\6GS^Z>_PEUZ;$_M8&UC^BWN(_;7&/[Z:?0=UM^>LI^]N/ MQ:?/[I[_``EUZ;$_M8&UC^BWN(_;7&/[Z:?0=UM^>LI^]N/Q:?/[I[_"77IL M5T<'_E-NVS.>:,2X5@]MV>86:R[DFRL:Q,Q+26.CQ<3)7M<,?;K*2DB,[E6> M'8,G$@514$B'4%,H\I1'0*PNI.YOK#36GK[45SF^626]A9S7#FM;/B(PS^:,Z=^.2D6AW44& M!B!R',?G,'#34:J1QF0T!`5&:9L(!<":E1Q__P!_]NW_`-D,W_KL?_OOJMYJ M[PC[*M_/X_N7?87:0_G[;87;]!O-8FSG"1ZARE7DR1]CRP-2CKJJ=DSO(KM4 MA.&H)@<^G841X#`VK^@A1%]%TAWV/^*E]PGG/%>XFP(O)N';OCKSL^4.JW*^ M9`L@[CI)MR=]AIN+>)-Y*%F6(G+U6SE)-4H&*8`$AR&-0UV6W:+%X]-8GQN<&T.TT4XM6RO4HB41*(E$2B)1$HB M41*(E$2B)1%&]O1W!7;#2EO[=\-&&ILJS&QY%\J"]W,7/,#99(C22WBG)9'' M&[^CFG`/7 M1QU`#/Z60AAJ&N!O3MKVK6/M]@6[DK1G/9*D6H&N>]W#8%71G"Y0.YBH`ZQ# M*QL&BH(A[(@L[$.HL81$"D];Y`=V[1_)#)63MBBO=?7$=;O,'-J\O<*OBMRX M8HH`=FRCYB,O*SN45&Q`A"[C=V!BD(437`\YA*4"B;_W!NKM$ M`U&N;/;-^*0+YV3$(7=7NS,!" ME,:7GN82E`##KD>:UYA`-1$:D[HK6M[RG,S"`/\`J[G]:7"FYW.<>5&D02:" M&+XG$I5]?C_6C\U=*5J@HH<.YY^CK>GG'&%PO>E9^2\G2R4:HNIRMX>^B=%" M,6#FU*DC<3SU?RZSR;#I?/]0S"$N/DP9@, M+8SX`VZ:!`[PR"#<*K;'66@?VBY*9'JK+V5S?+,L87T&V2U)<7CT3"29!_R& M3T%O[6R$+OSW3&`A2F%*^>8P%`##K?D#KJ(!J.M7'=U8P=]+F.X`8L-_MI_\ MA;*3FDYQY`Z4J32MM\5E4J^OQ_)_C)R\E,B==THBHH"1`3+P`NG*K7VF+SO(= M[W,>5^K5WNU^-E\";R+ZV M[PUQ24S8+F%?O2-9$P`!'36$B[BBY(&J($9H2J"#U1JNHB1,K@@@8Q>!0+F> M[O89IR6[U><IZ]1G%23HG`0]MNR76*/9V@8E=+,WN76>4W5VSMQ6\CQUM8YP^TM3K*(3WD M,!W/E8WTW`*-_P`L-L4^,LFS1N+N5R(B1R?34Y@;6^P<$`PZ:B`*R*@_&8:T M'_V\(&OY?ZAS9VVYN<^`<>DAEM$X?SI'GQK9/O0R.;J?*[,>\Q9;Y(\%97@_ M88`I,^T![?D']#2NA"UC45&52$'S+L.G%,O.%O6_H<2AS!I#WI^JTUX`-0,?F,&VFWWC,.E;8:2)^C-G0J:><2[/Y=JF8DTQ\R7"!Q(43A! MVUH<2ASA]YWOZ=-0J7FNQOT^M'OH,7F=MMZ>QF'2I=&.<.[7GK=N'CS>VME* MMK\?R#\U=*EJBH?=_%HEO_QCOO#"WA;<7;@R(M^]@Q&7O.39%=F:B=+O M!415`PDYBB8`$`$*Y9=];2[=;]X31>C7S>;MS2PBM>+AQ\/C7TK,>"HQ!I-2 MVHJ-E0MP^0.!5ML_RI?^*\ MJS6T?,;I5TXC#.D[!DG*ZKGNZC-KXDG$,7KG1=S;LY":NXX#^TW,0R.@[6N+;&0Z*@J&L MP?.'2NG]4Z4@YNZ-8&12X?.V-`%<1P<1S1L$T6K"B"WQ6;&9#W;8"L>75<-8Z[K?M^WGSQD5OW]LTDKRFT%E6AG2*Z(+I ME,(EYR&*`]H#7+COAZ4R_7/>;T3H_-'21Y?F=E;VTCX\/$8R6^G:YS"]KFAP M&ZK2*[PMP>1>=76G>4>H<\LPUUS:7$LS6NKA+F6\9`=0@T\-"#X"%E;A?8[C M/!M\DONW+EO25DTX:7@^Z3!X,&1FLRBF@Z4YXR&8NBKID3#D$%``!'B`ULIR MF[GO+[D_K!NL]/W^:W&8-M9K?!.Z#AEDX#7'W*"-X<`/)(<*=(*\HUKSSU1K MK(CD&9VUE%:F:.3%&V3%BC)('ER.;0UV[%DO8M@0V/V;]E#KOETY%V5VL9X* M0F`2%,1,A"H(I)ZZ',)C::F$=`Y2E*4NPND=&Y9HVVFME$7)09O'2;M M5JS=NDF#<';]5LV7728M3+)MRNGJB29R-&QG"I$P44$I!.8"ZZB`5(Z2-A:U M[FM:`F@VT%5.V.1X+F@EK14^AN'JCTUQJG4B419@^7K^/ML MJ_WJ\"?RFVW7P'-;^&&HOT)>_%I%]-HW][,M^'6_X9B_67KADN@:@*_*`OX` M\#_QSO?P#N.KJU[1ZE8W_8;UJ*'RFMJF&]V^:LF61FN'EYJ`MC%J=U1"$-<4 MM;:Z,P:[(:(,LJZB'#==PD+)ZH7IF$2:CKIJ`56G>YC06[ZJUM8F2O(?NHLA MO-:\M3$&T_'-E9HP6O;6P[OM.XIUS<:23J8BY63@YV%D)`II-OHI" MK-W2"JRJ9NJD=/D$IP/+!,YYPNWJI=6S(FA\=:5H5N>0GDZ<@]QV3<2@\7-: MU_XPPI!J)8X;2"H"2-W9<#XU<&\?\`RA=7[FYS_P`,=5*ICN*_ M/>VY_P`/V`OXZ<4?AY`5E7=AW4L#'[XWV0^VOT0S&*0ICG,4A"%$QSF$"E*4 MH:F,8PZ`4I0#41'LK%+/JQ,MNEVS0,@I$S6X;",5*(J&16CY#*ECM7J"Q!,! MTEVRTX15!4@E'4IP`0TJ;`_?0TZE(98QL+FUZPKMVY=-LWC%HSEHW%!73".! M,5O,6Y+Q\Y%KF*`"8J,A&.'3142@8-0*<=-:@01L.]3`@BHVA=?,7]8EO/31 MD_>MI0-O1,"^70.=)9!E+OI%!@[7253,4Q$U M#&`Q1`0U`:!KB:`&J@7M`J2`%S+&R7CK)T:M,8WOVS;_`(ENJ5!S)69WZT9\UJ75 MG'$-MW.186ZMO3N2+/B9I%P`@7H.(Q],(/&ZPF,``4Y"F$1X!40QY%0#12F2 M,&A<`>M7>;.6SUN@\9N$';1TBFX:NFRJ:[=RW6("B*Z"Z1CI+(JIF`Q3%$2F M`=0'2I5.J,O7*&-,:MT'61"H"2-VP.!/6KT"(``B(@```B(B.@``<1$1'@``%2J= M4.UR=C5\[;L&60K&>/G:Z;5JS:W9`.';ETL<$DFS=NE('66754$"E(4!,8PZ M`&M1PN\!4,3?"$<9/QLTO./QRZR#9+?(,J58\98JUTP:=X/R-V*\FN=I;1GP M3+@B,5MZV;\G30"X?X:Y==VD-YD=[G6','-QQ+C+Q= M&W#MO#+YQ90TKNX=K$^,>R*W`YL8M*\D,BTS8D-AN3"):;,0;&;A]:?=S/:X M]2EX^#AZ?7P^I741:@KZ)]>'#TE^'X0].GHHH'SA5/NC?63YF?"KC]:7"GYW?PHTC_8Q?$XE*G\/#T_`/'U]E=*%J@O/QD7$ M\[EG@47<\:BRA]UF5O&SM3.M[BW:^)A&T2F-[GPD;3*QK?7 M+H-I[5]EI'EMI.7-6M^2KYL5I*YVZ,213%KW#<68VALE=S'./0KQ^7;. MXW*-USJX.IJX<>R4K+.P3Z7>G[FZ;:,Y^R.6:9X&'%(Z[M,;J=!<1B6^59/8 M-P6-MF+(XVUKA8V";"*](`V#T`%-)Z`X!V^OAV^JNM1W+2A15XJ_K+,Q\/\` M5^XOS_V'L>N;7+3Z_P#JOX!9?HY_P"K;92YA]5RT^%CXW*I1I!H$@P?,!T`'S%VR$=! MT+WMNHWU[.P.I71F_M1?6,UD[LS0O8?Y;2WU5JU;RFWG9.-['M=]Z0?448WE MFOQCHC-F/WFB4G;=YQKY5J?4%"@JU>P+L>40U#I.X'E'UF"N>7^WO>&PRS5V MB;HX6'?M8^W?Z3[:A\!(6S_>;@%U=Y'J&';:W-B]H=T;"V5OIMEKX ME*-\/K_-Z:Z,+5I1595'_P#TLPZ'_I^`T[.'[#7IZJYMU2']WZE=*%JBHKMVOX[.U/\`ZVS_`.4)X-\W];KEK[*S_`%B] M;489.`,[G?9B3#OG\_@`UTJ6J` MW**_=+^/7M7_`+VSOPYF*YO]X[ZY'+?_`-E^L)UM7RK_`($ZL_\`/^+1J5`> MTW#X?0/'X^%=(3O6J@W+YX<.'U!X?4J"BM0]/#3]/Z@41:?#P]/P#Q]?91%K MZ?T^/Z.E$6G#3ZT.WLT'Y=.6B+FH_6?GC1%NT1*(E$2B)1$HB41*(E$2B)1$ MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(O*=^5@_BM;6O]X: M7_DRN:MW>XY^^V=?HIOQB->#<_?W>L_A1]JO"Q72]:GK(;:[M=S'O"S%;N$< M(6X$Y=VW.KFM!.<[;-@TWIR%SS()W;8GSM8,;I>S)-Y-6@`/`/#MQ[?81 M96RVET1I-\8L2RN99B\##PQV@PNV"/:0P5J\FH-"Z4P<[F=KD!&R6:_@'<=75KVCU*QO\`L-ZU"UY<^]*W-CV5+\R'2OA_(4";B5AW:>R_>QNLW(6HZW"8OW`0I\H7JU#(>6; MQQWQJ2P]*XWO*ZKG@,E$NQHHVO(L.K.0DY9Q+=<&=L MY6#C(9!5E(H3X"4@H%5041X*'`X%-7ST]V5]1-V6AM3LBXG]O6N[L]M?F4QAGB[%[0M!M-QSY&W'KF&\5N=^>39NF[.1GF"Z14VJ0J)()] M7F.8P)A/)/PWX:5\*IPVG%CQDTKN6&VS?C38J,,CH9* M]%:$+(WSLT&CC?MO&5/ M>?W@]05SL&^6)-;D]AL?N)G,X3[63LZSLGN\-XR-$,WUDP%O6=<=V/Y"'745 M6(\8.[ON5F_<*K-")BD9R0Z@..7E"#IL$N&G3M*G9;&6#B%QV`T'111O;1I; M+YLV618>#LCSF*;GSG*1>(9"XH1VLT*6"OMXWBI!610;G)WGPQJN9R@-[2+WF2?-UI^V;JE7]IV^D M7JN@9RLM;:1FS-+V2.72HIE`5!`:%RT8P?"KBR>[AN&\-W**%GM%WS;M=Q]M MR^?<3Y]AW65;]BFM[9+NS&]T'B["MV5D"C(.&I9)JA&P\%;,6)DV34#HM4@3 M3(.@:B-?B1QMHTC8%:\&:62KPZI.TTW*YGF?^7+CW8^RQ%<^-[SNVZ83($C< M$!),;U3@UI.(FH!A'RC:0CI.#C(9([220<+`9$[?G0.B42JG`X@6$,IDJ"-R MFN;=L-"TD@^%2[^2EN$R%F/;7E"QZ+:DBL6[@\=/0LJ+^)?IH*)'3669OD2*$*8#`)RAJ` MAPJ](J*'<5BP2TAPWA2/-?+%\PP;1DMRY[.D6UT$02R.B52^BCG:0?&D&DV: M?;QR!EI$ES(`!GIFZ[U*1U()"I"ORHFI<:*N#H^PKCS:XIQ:;=_HJ8G('+\]L M?=+_`"MK'2-&\<%I@N!XFX9J?<"JF'UTX<>'J'YJZHK3E:E,`&`>/`0'L'T# M\5$4+6''U]:]K*4A9%(,1V8HWQD.: M2#0U%=QN5Y?7?;NRSN.RTUCG;.UKGEE4X]9V7B+Z8NB6N3P[J$U16=Q\@=Q\7>J>9VO>9UK!)%IS,;HB)SQ_23W<]UPZCR7/BB%,.3Z1TWI":1C\VM807AI];'!'#CH=H:]X=@J-H:?`I6M0]?R M#\U=*UJFTO57-OD#]=SF#_97OQNS6U7,NI[ONEZ M_=P?@9UP=IK!C%;Y=SD=&M$&,>S;7RDU9M4RI-FR7O\`PA^F@D0`*FF!SB(% M```->%6O=HLK3+N^-S#L+"-D-G$S,`QC`&M:/E&V-&@;`*DF@V"NQ7'-FXFN MN1.E[BY>Z2=[K8N/\` MH"X>'_T:Q_17-KEI]?\`U7\`N/P.7K:W5WU:,E^$Q>WNEN6U_6A7?^YA_P#R M>0%39!_^B69?HY_ZMME)F'U7+3X6/C]HY=M]B5UZZYGY5,>1G?DN\O MG]RTOK..K#2C>)=GB1D='DW\4L7H";T:+;*\9\XG=WANH_+SC('T(&TX(!A= MZ=L]C_1,:EB^'MU#T#J''X.RNF"U-45.5=!\RS#H_P#I^WQX?]S7I7-OF3]? M[2OP"#\!F"VNTG]6?.OA,OM[5?68OZR3"/\`W';8_P#8[W]%4^:WU^=(?`[; MVF8)HSZMF>_V\WMK92IZAZ_D'YJZ4+5%1&;Y+HC;(W6[>+SF2NCQ%JP\'<,D MFR3*J\4915[R+MPFU24.D0[A1-(0*!C%#F'B(!7+_OB:CR_2'>4T)JO-A(L-R5TJDLX*V=M8M ML$J5MX8#R*8JK+=,YTU'<@Y$R9="`4?F^1?,'2_.SO1R'D.=@>R)O&P\+B0QND?A+FNFN)2Z-M&-:VDN+%QXF M8W3<((%6N><&+'A>\-;B`(9$P!QJXD3/:@'H']:/S5UD6EJB4WE7'#6AO)VY MW7<+L6$#;L5;,Q,/>@NX%I',;TF5G3CN[9-5PMTDRB/*0IC#Z`&N8_>OS[*M M+=ZS06I,]EX&2V%M:SSR87.P11WT[G.PL#G.H.AH)/0%MOR8RV\SCDUJ7*.]TF#$:BY6:[TEE9SC4%CYOES7M87\6%_E/J&BC'N= MMH=M*#I60&H>OY!^:O;EY^FH>OY!^:B)J'K^0?FHB:AZ_D'YJ(FH>OY!^:B+ MF(_6!\8T1;M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41 M*(E$2B)1$HB41*(E$2B+RG?E8/XK6UK_`'AI?^3*YJW=[CG[[9U^BF_&(UX- MS]_=ZS^%'VJ\7N",$7_N*O\`;X_L!&):G0C7URWC>=UR:5O8]QA84*":ES9( MR5=CL.X6M9-M-E`.YVUMV8K=*=3#?E:[/8Q`<7;&<;SSMU>.X3(?3>*6M M`W'(1SBWY?(=\S;]RXG[QNQ^I&Q$:4YTD.YJR1#*>-9MH'4&F!-/HL#,.=6? MO/G.<7#`(K Q'QM<'M@A8T-AM;9@DED(#G<1L)I]Y8ZDRS-@V/.3YOHC+V M^Y6<;CCG?MP@D%I>][B72RNP@"H`89&@X<[M]FMW8UQUCW=V6U[#PMC+=O>= MXW5@3:JE?,Y=N;;`PXZ-)S]FW%,Q4M%)2,A8:\`V*5M*F754.FHW.J4@+E`O MH.A.8-CF^;76@S-=9CG.16\45[F1A9%9S78PLEC8YKL+9@\^5%A`!#PTG`:_ M*ZDTO/9VD6H6,AM[*^D>^&VXA=,R&I+'$.%2RFQK\1+AA)`Q*V7EZ\=^NRD0 MX@.ZK`?\IMM5F>:W\,-1?H2]^+2+&:-_>S+?AUO^&8OUF*X9+H&H"OR@+^`/ M`_\`'.]_`.XZNK7M'J5C?]AO6HL_*(VQ85W3YPRA9N<;25O"W; MC'P$P[LO M,!\P#.\'C>T(VYCZPKKE,O3O'BP)^R`F,1.K_!%$W$1L'C6)XL\\F$$@GH&P+K=_>S3<-M0C<4/\]9 MP;Y@6R`]N]O!-F]RW[_3$OB2OU5*QY%'XLNZ_P#=X/\`)BQJC==IO4KJQ][?U^HO/#MS M_A^P%_'3BC\/("KIW8=U*PC]\;[(?;4@OG5];_;YO/J]3D^C?%W=N?FY>AX, M[YNCKPZ?>.IKIPY^;TZU2M_>AUJO>>_GJ"]%/E+F1-Y>NW'H\N@0MZ%4Y=0^ M[ADV]06UU_5=376K2?WTK(6G]W;X_MKQK;BS`?<)GPS42&`V;LK"V,GR],1& M_P">Z(D_4\O-IZJR#.R.H+$2>^.I]T?MK.GSB.\?[9RO>Q*+OZ$<,=Z$FG(+ MCP!YUA+RZ%Y>IKIIPTJE;^]^,JM=^_;=^$*=[R[?ZI&W_P"++<)^%>3*MIO? MSUA7UO\`W0=1]5>8+8!^.=M)_CMQS_XHA5[)[V[J*QD'OS/9!3G?E"7_`)%V MN_NXR1^#NZ@KZ_[+>LJV'D?Y$@L183WU92N<5?=_'C"P[RER(:=X68 MV]:N1I19LV`WLBZ=E;=)(!X"H<`J-R"YS6C>5+9.#(WN.X?^*P*F-Y>_C?KG M6"Q[964;MM%_D>X%XVS<9X]NJ1Q]9UN1Q$WDH8)>4@E&LK*-X*':JK/'[U5R ML;VZ2?WRV."7,BDF)6Z#S-V+6CI%-P MU=9DL)NY05*!TET%[^B$ED52#P.FJF82F`>`@-73NR>I6#.V.L+]%.L4OH%@ MIO+VQ.,Y6Y'7790)M,JV0DH:$/U@9#<<4"O?#0!WO.4&D@V>%[Q'+F,!4EQ, M01*503DU#[U_=XGYQ9#!J72-(N9&3M)MSBX?G,(.,VYDJ,$C7CB6TA(#),37 M$-D+F^V\F.:$>A,RDRK.ZOTG?$"44Q<)],(E#?7-+3AF;O[WWJ;;4)CY9\X@_)N:5FX6Y==,,#+Q[/)&(O`$-V:>7$\ALKO+A<[%@; ME>9W)R7*P[5NA<-_HZ<&4"%PD=`UVW9A)+X1ZUXJ6#R9`,.(R!<=1X#]3_"K M=Y:^J,'S08B*#&%B7"$6P"?+>PQ/C16:`2WA1K;GG@QPOR$[T+'O:)5.D)A( M!R@(``USN_W$\JRWYN\GSMMM#\MC-Q#QQ&WC<$VMR\Q<0#'P\;6NP$X<0!`J MMH.ZY>7?[57V7F5_R>;$R<,N/#QB:)H?@)PX\)(Q4K0TW*0+%\-$P..[(CH. M*CX>/3M:!7(RBV;=@T!=U%-%W*_0;%23%=RN]37MYF&H+VZ MOY9)KEUS("][BYQ`>0!5Q)H```-P`H-BKOCQX#V_F_55]HL&HK=MW]8)N8`/ M\QO7\*+3KFWR"'_>YS!K7WJ]^-V:VHYE$_1^TQ_:0?@9U\[7/Q\=TO\`U5\A MZ>WW\@?B_1IW=?KH\QO8W_Q^U53FE_`+2G7;?%95*IQT`-!^/7_&UKI(M4U# MME>X+FVK;S[GS=.V5+W-8E\QJZ;%_&_>Z"J,E#0K1ZV2D5$E6+>8B9*&#F;K MBF*J!P,40Y@$.5O,K.]0]V[O89AS>SC*+K,-&YQ;.;')%Y+2)8;=DC!(08VS M0RP;8I"TOB<'-.T$;C:4R_+.:_)>UT18WT-KG]A*"YDFT@LDE+7%@(<8Y&2[ M'M!PO!!&RB[[:TI=V==W-Z;DRVE(VQ8X0TBR05D"*&16=.8:+MV,BVCXR2*, ME(`T9FYM26-Q. M#&!WE.VFFPTEKX\.`\/B_P`*NG*U'4;_`)D5A'?8YM'+,0!VMQ8WN=FV&0;E MY5TH>><)`W5%4HZ@,;<35HHF/ZD5#_#6@_?ZT6^[T%EG,S*JQY]D&8QCBMV. M;#<.:&NJ/ZJZ9`]O@Q.\*V2[M>?MAU+=Z1O?*RW,[5QP'LF2(&HI_P`\+I&G MPT'@6;&&[\#)V*K!O\2E(M=-KQDD^3(``1.4Z(-Y9(@!H`$3DT%2A\`!6V_* MG6;>8?+?)-:@`29CET,L@&YLN'#,T>@V5KP.I>):RR%VE]59AI\[6VET]C3X M65K&3Z)86E1T;Q&]U8@W-XKW*M[7?W-9T3&1;"3[F50$FK^+---'<<\>)I." M1BSZ+F`5:++%Z1U4S%$?9$*T2[U%OJ7E=WA-.<_[?+I\QTI:V\4`X1&2&?'"]XP%[7-.Y;&\G)LJUARPS7EE+=1VN=32O?'C(\IKQ&YKVM M)!>&OCI(UIQ!I!"I?%=P7'NMWF6MFN$LN6MJQ+`BVQ'CZ2'O"29(R,F4&35: M13338N)>5E)@>5N@8XI-TQ,8>`B/S?+C.<_[RO>MR[FYE&4W67Z,R2V:'R2^ M4!PHIVQL,@`C=-++.:1QEV")I4W)BZT1?7L-SG^83$M8S83C M?&7.#22X1QLCVOZ@'0IB./'@/U/\*NJ2TY44.\:.CYC>3M@B99BUDHN3 M1M9C(1SYNFZ9/63F_GR3AJ[;J@=%=NNF82G(8!*8!T&N:7>JL+'-.]9RZRW, MH8[C+IVVL60SW=J^1MK M"R!KW-S*)K7.;&UK2X-)%:5ILW465Y59YG.?\IM4R9[=3W%3`'UYCM=2EIV-RB4\P2"6@\QX6RQ<%G.+QQM%Q M[:'N>.(D8[)Z,7<+J5=0529KH"VA;!>1!M8Y.%*0\,OHUQ8X5V+;CN]W\=[HW.])9 M?>ML]332&2!Y-'-QQ",2L&]W#>WR@VI`(--JK':OF;;9>^7F4!C#;V&.+L5M MZX':%T!X2`HL&J+-?4]V[FMR"U=S0BR;EYH?Y"U* M;&X>V[I",,;`SB1^YN+O=`0-U-BPW-71G,W)-'OOM4ZA^4LH%Q$TPUD-7N)P MN\IH'D[5)SQX/`?J?IF&B)QX\![?S?JJ(M>.O8/U/\+2 MB+3CIV#V_F_5ZT177\J4M9S=NW#:O'DD(V#CD-P M4R\G+EG%5D(*VXA+&EQE=2LHJW1<.5")\X%1;-TUGCQ=&K MCN`#-IZ?$!4G<`30+Q@9`S%VTC:>%CR4?-7H]>D19WQGN[H<3C&W MAE1=FLN1.#@553FMRU45E8J`(<5C"[DE'#]7H7E6FY'9K^U&HBR?46!S(0*F M&RB=VHK8$#RWBG'N2!),1A'#A#(FZTW^M;ZQ M@):W?M<7/=CA7V"^<2B+4H\ARJ`!!,0Q3!SD(H4>4P&`#D4*8BA!$.)3`)1[ M!`0J!%10[E,'%IJ.@U6=VV_S",^;;\EY0S?:[FV[WW#Y0LHF-8[-V9D7N0)C M&=MR+A`LZYM&*EEEX5"1>L&31BDJZ0=-(Z+04;(-!36.4/,=7\J=+ZNR>RTY M>":VTI97'G#K.T(@9<2-!P"5S0'EH<7/(:YKI)"U[I*M!7V>1:US3)[V;,&E MLF9S,X8FEJ\QM.QQ8'$MQ4`:TN:ZC:MI0[,WMI&V#%N3-^.V>YMACK)N5<8[ M9+VVTWUNLS%E]W9V/+;E+ZWB,XC/Z:9E(& M8VU<*KZC(`L#"HT>I6-_V M&]?J+"[R`%DE-S.;`3534$,%)"($.4P@'O\`VWQ$"B.@5/==@=:HV'OA]CZJ M]9-62RBQDWGXKF\V[4L^XLME,R]RWAC.Y&-NM2G!,SZ?:M!DX:.`YA`A/$9) MBDAJ;0H=3CPJ>-P:\..X%4YFE\3FC>0O%-LVW"*[/]S]D9AG[2DY@EBNKGMZ M\;.-RQ5Q(,YR%DK9FVB24D")64_"K.NJ"#CI`91`4CF)S"8N1D;Q&%HZ5AH9 M.%*'D;NA9=>9ANZN'?%$X\S%:V,[GL7;EC6X)?&]M7'>"L>F^NS)UWQI;AG0 M03CW#IATHRWK213%-NNY!`PB*RA3K$2)3AC$=6DU>55N93-1X%(QL\:D$\B. M39+[<]W,I7%C[V_ MK]1>>K;DY;#G_`(`X0$1S5B<``%4Q$1&_(````YN(C5T[L.ZE81^^-]D/MJ= MOSW]L5Y+WC8VZBUH!],6@6SV^/:BI^+908H7(\6FDX:YDWGW^R:QT\\<*=9H5R91NJ!`3(8G,:>2# MB/Q`]:IP78BCP$5/0L#MGNWK(.\[^K9Y,\ZK9@V,IUG#A+8J$4;II`!NK4^JLGO. MR5;H;];G2ZB*0$Q;BXI4Q.0G*0(^4`H`34-"@`<*DM_>O&55O/[P>H*VW]T'4?57E_\O]PW M-O/VCE*NB8PYNQP``"I!$1&40T```VHC5[)[V[J*QD'OS/9!3H_E"JJ:=B;7 M.HH1/6^,D:9%BNWE$ MU)V^;/M.WX,A5TR$4G7EH9'\%;JJB<"(I.9,B29C&$``IA$>%33G#(QQW!4[ M5N.&1@WD?\5%UM1SA([0MT%@Y9N"T9)^]QA/SL7>5D.=(BX$D)*&E[3N2+Z; M\I`83L6224.FFN!""NB!#B4IA,%>1O$86CI5K$\Q2AQ&T;PLW_,MWCS^^JS[ M'R=9&+;ILC;AB&[5[.2NZ\5(U)[<^5K]B5WXQZ!(UV]C>C#6[:2GW-!PX.D9 M<3+F3%5%.J4,8C):35Y'V%7N93,`X`B,&E?1*S?_`"?V0:+6!NX8)K)'<(SN M.'IR$5(800=6W>+=,_*41,`=1D<->RJ=UO;XU6L.R_Q+SX8<. MC71Q5=,8]RL;E`ZKADU74,!.!`,=5,QQY0``#41TTJSGR[+[E_%N((7R&E2Y MC7$TW;2"=BJLGGC;AC>]K?`'$#T@5S-0X^T'J[.%7@V*DMAPV:NR%3=(-G1" MCS%(Y017(4^@EYRD5( MM=>WV@[>`\.'JJ*+C)LV22ZCI)JS2)BNFFLD?^_35`Y#?)5.6**>,Q3-:^,[PX`@^(U"F:]['8F$APZ0 M:'["^B%333(DD":2:90*FFF4A$TRA^I(F4`(0OJ`*F8QD;!'&`V,"@````]` M#8%`DN.)Q)<>D[2OK4.'M!Z^SC\U3*"QAWG]V':]F'O7(8@6^R%+GTX.PGXC MN7)K_P!(#GEY?3K6N_>R$![NVJ?.*8/,64K]WYQ#@\>.E%ZAR6XOSHY-P:XO M.75]CPI,7BPU75;&`7+M9Q?WC7_FKF,AS?YJ-VS8H:?8\O9ZJQGQDC#'(`YA%""*@CT0=A7DP):0YNQPZ5\(I(-DBHMTT& MZ)/K44$DT4BZCJ/(FD!2%UUXZ!4D,,-O&(8&-9$-P:`T#Q``*+WOD<7R$N>> MDFI],K=U#C[0>H.'"JJE7%69LUEDW"[5HJX0T%!=9L@HNCH;G+TE5"&43Y3< M0Y1#0>-6\EG:32MN)HHWSL[+BUI]L;MX!(!ZP M#0^-%F;)RJDLX:LUUD-!167;(+*HB!@.`HJJ$.=+0X:ARB''C4);.TGD;-/% M&^9G94Z9P,0P?&`U))'',PQ2M:Z-PH00"#U@["H MM*@`JM)=7,K<$LDCF>`N<1Z1-%S=>SVP]?9Q^:K MU4$`0XZF`?@[.%$37M]H.W@/#AZJ(M=0U^N#3X.'RT1::\/KPUU[>'R41 M8=!'LU&MW>XZ!^VV='I^2F_&(UX-S]_=ZS^%'VB\*]=+UJ>E$2B)1$HBS)\O M5X\#?3LOC0>.RQJ^[7;X^7CBN5P8+O6F2[?3:/%V0'!LL[:IKG*DH8HG3`Y@ M*(`8=?/>:T M&;^W-.BHF90^*I7ZQ]<-5T!5*7;8=C7\T:L+ZLRU+T8L7(O&+*[;=B+C:,WA MDCH&=-6\PS>(MW(H*&()R`!N0PAKH(U$$CX+AL*W)&8>'3TY#/Y!>/ M,YD!(!0`.N930`T[*G$CVB@)HJ;HHW&KF@GJ5PW^*,6RMM1%F2>-;`D;/MXZ M:D!:C^SK=>6U!J))K(I'B()Q'*1<:=-%RH0HHI$$"J&`.!AUEQ&M:FJF+6D8 M2!15$-:WL@!4HSV^8#CG;1_'X0Q`Q?,'+=ZQ>L\:V8V=LGC14B M[5VTG-CVSJY)16:FM ML6#7THN<%%W9L;6LB9=0!`>HNFVC445E#"&IC&*(F].M3B20;`XJD8(2:EK: M]2OU9MA6-CJ');^/[-M:QX),P*$AK1M^*MR+!0"%)U>XQ#1FV%42%`!.)1,. MG$:E))VG:54#6M%&@`+I+FPYB*])4\]>.*\<79.*H(-59FYK'MB=E5&S4#%; M-SR,I%NGAT&Y3B!""?E(`CH`4#G#8":*!8QQJX`GJ530]I6I;UODM.`MFWH. MU4T';9.VH>%C8RWR-I!1=5^W)#,FR$<5!ZJY4,L0$^50RAA,`B8=5234[U$` M`4`V*B(G`N#("2CYF"PQB>%EXERB]BI6)QU9\=)1CQN8#-W<>^9PZ+IFY0,& MI%$S%.4>P0J.)QWDJ41Q@U#17J547=CVP,@),4+\L>S[V0C%5EXU&[K9A;D2 MCEG)")N%F*D:*KIIE*:H& MM;V0`K9Y"VJ[:6I&6&[QK8+NQX15%>&LUU9 MUO.+5B5FY%R-UHVWEHX\2Q60(Z5`ADD2F*"AM!]H=88G5K4U4<+:8:##X%RK M3QKCJP0D2V+8-E66$N#24#6M[(`5*M]O>`F;IN^:8/Q`U>M'*+UJ\;XTLM!TV>-UBN$';=PE" ME61D%=^I5.NNT#U_*/ST1-`[./RCZ M_7ZJ(@``\>/RC\]$30/7\H_/1$$`#CQ^4?GHB:!Z_E'YZ(F@>OY1^>B)H'K^ M4?GHB:!V/SF0?])EUH]Y<=P?+[DS^ M:9'?R5EG@ZRCXZP]C:R5BBF[M^SX9I(D[!+*+-2O)4!T](2+E6MF>3VDG:$Y M6Y!I&08;BQRN!D@\$Q8'S?\`JN>O)=<9V-2:PS+/&&L5Q>2.9[`.PQ_S`U6H MRA-S3&[+\/%GR0:0A;=LUW;[NV'4B>U+<Q#66<3$E_MX>T8<8F#FIR[KGR,S9O MG4_+]SC6MORTPZ5<2:JL:9XJ@@=,6S=)(!$4@2XEU,!"*L_?2])%O,SEM6M# M25M0;J78@#V<>,I^Y'%OK.&N8"I%)H M8P"80(!%O-,GO)>1LA"*C(EDUNV!83NER3#J.?QS>:E7V0&5C6K'M;@E]7+I>,A%(N M+40?H!#PD4V0<&=N'*29EBB*_LG`"3 M+N6C"7(\M"*86]&7,2T;D(:?=+S'B2=QI6K(R<`DG&E9.H5E*K`).\'1<+HE M.;E((%`Q%T\IG5)NO.O8X+15A;>DY2.5C9&YG+*\IPL&Y5:2CN'CB1RT:AS. M&ZI62#A8%'8$`1,ESEHBKDEY7+<$F^;V'"P[Z-A21?B,I<\I(1)7LA*1;2<1 MAXELQC7ZI%F\6_;G77<`4B:BP$`AQ*<0(NSQ!(2$I8[=]*D>HOUK@O0%VL@X M[T[8BE>4\B2/57`YR*`P33!$O(/)R$#E]G2B*YU$2B)1$HB41*(E$2B)1$HB M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B*)SS:_+*>^9YB MK%6-668FV&CXUR*\OP\PYLA2^"S!75KREN^&%9)W1:PLC$&1ZO5ZJNO)R\G' M4/6@AP";@X:2-DQ5XS2E!OK5?`\P-$NUOE\-B MVX%OPI2^I87UV4I0/93TRH'O[)1/?TZ(K_A]=?SNULW].JV_TT_\N'^57DWT M>Y/SHS\G/XY/[)1/?TZ(K_A]=?SNT^G5;?Z:?^7#_*I]'N3\Z,_)S^.3^R43 MW].B*_X?77\[M/IU6W^FG_EP_P`JGT>Y/SHS\G/XY/[)1/?TZ(K_`(?77\[M M/IU6W^FG_EP_RJ?1[D_.C/R<_CD_LE$]_3HBO^'UU_.[3Z=5M_II_P"7#_*I M]'N3\Z,_)S^.5X]NWY+]-X(S_A'-RN\V-N9+#^6,?Y,4MPF#7,4>>)9%T1EQ MFAR2ALI/RQQI((_H@N*"W2Y^;D-IH/S^K.^=;ZFTMF6G!IY\)O[&>WXGG@=@ MXT;H\>'S9N+#BK3$*TI4;UD\FY&293FUMF?RDUXMYXY,/`(Q8'M?2O%-*TI6 MAI6M%ZX:T26PB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$76 M\/LOMZ(G#[+[>B)P^R^WHBB)P^R^WHBB)P M^R^WHBB)P^R^WHBC`W1>Y/^UM@KZ6O?/WZ/=O`/<7K M^/??OC/7_9GG]X.Y]]T_R;HZ>QK7._O%_L;])G1OSF?*WR+BM_,L'FWR=C\X M\OCXO=Z^<\#CT_HN%ZVJV@Y6_+WS1Y_^R7F7RA27SBO%\ZP\+R>%3W.G"XG# MKZ_'ZZBE`'M'7FUU'7Z[MUX]G#MKH@M7ANV+&.^O>[W]OCW4]Y_#/=>U??7P M#W.\0[AW:>Z/@/O#]]^(=P[QKT^/-R\GMZ445HCXGWI3Z!._^&>[5I^/=;P3 MPCE]WV7NSX1[P_=O>[W6[MWCG^].ET.O]THBO[9_)[MP')[PZ]P;\_O7U?>/ MKZCWCQOG_P`O[QS<_+]RTTZ?W/EHBM%:?A'B&+N[^+=3QS-/<.MW33K^+ROB M??>G[73ZO-W?I\=-.?CK1%3XOO+]&?B=R>\'AWN[XMXKU'/OE]'? MB7W]W'Q'K]7G_P`JZW<^.E$5;X<\+YW'A?B6GN)A_P#TAW;_`.#]UG?ANG=_ M:[UW;7O&OL\^G)PHBM@OW_W+QKIXQ]%W)9_BG6]U_%/$_>XWA/@VO[+>*=\Z M/>^A[7==.[_=.>B*NIKP+PC(O5\>\2^EECX%X3W#QGW[\(M3P'P#O/WER=3D MZG?/N/1Z_5^Y4143/^+]PNKZ7O&/>'W%F/=GPOP+P7P+OD1[S>$]S^Y^\_4[ MIWKO7#N^G0]CJ417\=]U^E&`Y^]^(>X=S]+EZ/NMT^33V M.3FUXZ416\=>%?1;=/\`I7N7TER_5Y>Z=][_`/2ZES]WYOO?N?B6G+S>WT.W MVZ(J?=>]_4N3W%][OHO]XIKQ;P7P#WB[UXDY]\/H][S^R7AOBW>.W[XZW5[G M_P!'1%W,U[T>^-P_13XKUNG#>_O>/!/"_%?"VWAG@WO%]W]\O=_H=XYOO3DZ M'7^Z415]A3N7T=QG